BRIEF published on 10/05/2026 at 13:17, 23 days 13 hours ago ReproNovo Named Among "Fierce 15" Biotech Companies of 2026 Biotechnology Fertility Women's Health ReproNovo Fierce 15
PRESS RELEASE published on 10/05/2026 at 13:12, 23 days 13 hours ago FIERCE BIOTECH NAMES REPRONOVO A “FIERCE 15” BIOTECH COMPANY OF 2026 ReproNovo named as one of 2026's Fierce 15 biotechnology companies by Fierce Biotech for innovative therapies targeting male and female infertility and women's health Innovation Biotechnology Fertility ReproNovo Fierce 15
BRIEF published on 07/06/2026 at 07:05, 3 months 22 days ago ReproNovo Begins EU Phase 2 Trial for Embryo Implantation Treatment ReproNovo RPN-002 Embryo Implantation NORDIC Trial Assisted Reproductive Technology
PRESS RELEASE published on 07/06/2026 at 07:00, 3 months 22 days ago ReproNovo Announces First Participant Dosed In EU Phase 2 Trial Of RPN-002 Embryo Implantation ReproNovo doses first participant in EU Phase 2 trial of RPN-002 for embryo implantation, aiming to increase IVF success rates with oxytocin receptor antagonist ReproNovo RPN-002 Embryo Implantation EU Phase 2 Trial IVF Success
BRIEF published on 03/20/2026 at 13:05, 7 months 8 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
PRESS RELEASE published on 03/20/2026 at 13:00, 7 months 8 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 1 year ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
PRESS RELEASE published on 09/30/2025 at 07:00, 1 year ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 1 year 3 months ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
PRESS RELEASE published on 07/01/2025 at 07:00, 1 year 3 months ago REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
Published on 10/28/2026 at 22:35, 3 hours 59 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 14 hours 4 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 14 hours 4 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 14 hours 4 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 14 hours 4 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/29/2026 at 00:15, 2 hours 19 minutes ago Infinite Electronics Showcases Engineered Connectivity Solutions at electronica 2026
Published on 10/28/2026 at 21:35, 4 hours 59 minutes ago Food & Beverage Manufacturers Race to Scale AI Beyond the Pilot Stage
Published on 10/28/2026 at 21:15, 5 hours 19 minutes ago Amrize Completes $1 Billion Share Repurchase Program
Published on 10/28/2026 at 20:36, 5 hours 58 minutes ago Vonovia’s Core Business Remains Resilient as Higher Financing Costs and Weaker Transaction Business Shape 2027 Guidance and 2028 Objectives
Published on 10/28/2026 at 17:45, 8 hours 49 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 8 hours 49 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
Published on 10/28/2026 at 17:45, 8 hours 49 minutes ago Groupe CRIT : Revenue over 9 months 2026 : €2.55 billion (+2.2% organic growth).
Published on 10/28/2026 at 17:45, 8 hours 49 minutes ago Infotel : Acceleration of growth in Q3 2026: €77.9m (+11.3%). Confirmation of growth and profitability targets for 2026 as a whole.
